Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...

Pharmaceutical giant Eli Lilly & Co. (LLY) is buying privately held Scorpion Therapeutics’ experimental cancer therapy for $2 ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.

Several large drugmakers will ask the Trump administration to pause Medicare drug-price negotiations, even as Biden-appointed ...

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended that Keytruda's coming loss of ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 503.77% and ...